

=> d hitstr 1


L12 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
IT 291778-80-8P 291778-97-7P 291779-23-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of proline-contg. peptides, intermediates thereof, and elastase inhibitors)

RN 291778-80-8 CAPLUS

CN L-Prolinamide, N-[3-(carboxymethyl)-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291778-97-7 CAPLUS

CN L-Prolinamide, N-[4-(carboxymethyl)-2,3-dioxo-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291779-23-2 CAPLUS

CN L-Prolinamide, N-[4-(carboxymethyl)-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 291778-81-9P 291778-98-8P 291779-24-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of proline-contg. peptides, intermediates thereof, and elastase inhibitors)

RN 291778-81-9 CAPLUS

CN L-Prolinamide, N-[[3-[2-(1,1-dimethylethoxy)-2-oxoethyl]-3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 291778-98-8 CAPLUS

CN L-Prolinamide, N-[[4-[2-(1,1-dimethylethoxy)-2-oxoethyl]-2,3-dioxo-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 291779-24-3 CAPLUS

17/09/2003 14:26 Print selected from Online session

CN L-Prolinamide, N-[[4-[2-(1,1-dimethylethoxy)-2-oxoethyl]-1-piperazinyl]acetyl]-L-valyl-N-[(1S)-1-(1-methylethyl)-2,3-dioxo-3-[(phenylmethyl)amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib 1

L12 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:628158 CAPLUS
DN 133:223051
TI Preparation of proline-containing peptides, intermediates thereof, and elastase inhibitors
IN Sato, Fuminori; Inoue, Yasunao; Omodani, Tomoki; Shiratake, Ryotaro; Honda, Seiji; Komiya, Masanobu; Takemura, Tadashi
PA Dainippon Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|--------------------|------|----------|-----------------|--|
| PI WO 2000052032 | A1 | 20000908 | WO 2000-JP1022 | 20000223 <-- W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG |
| JP 2000256396 | A2 | 20000919 | JP 1999-56052 | 19990303 <-- |
| EP 1157998 | A1 | 20011128 | EP 2000-905282 | 20000223 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO |
| BR 2000008600 | A | 20011226 | BR 2000-8600 | 20000223 |
| AU 758739 | B2 | 20030327 | AU 2000-26902 | 20000223 <-- |
| AU 2000026902 | A5 | 20000921 | | |
| NZ 513594 | A | 20030429 | NZ 2000-513594 | 20000223 |
| ZA 2001006514 | A | 20020510 | ZA 2001-6514 | 20010808 |
| PRAI JP 1999-56052 | A | 19990303 | | |
| WO 2000-JP1022 | W | 20000223 | | |

17/09/2003 14:26 Print selected from Online session

OS MARPAT 133:223051
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

| => FIL STNGUIDE COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|--|---------------------|------------------|
| FULL ESTIMATED COST | 21.84 | 534.88 |
| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
| CA SUBSCRIBER PRICE | -6.51 | -33.20 |


FILE 'STNGUIDE' ENTERED AT 14:11:44 ON 17 SEP 2003
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 12, 2003 (20030912/UP).

=> d hitstr 2
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
IT 274918-59-1 274918-61-5 274918-62-6
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(prepn. of peptide-based .alpha.-keto amides, .alpha.-keto esters, and .alpha.-diketones as HCV NS3 protease inhibitors)
RN 274918-59-1 CAPLUS
CN L-Prolineamide, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[(ethylamino)oxoacetyl]-3-butenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




17/09/2003 14:26 Print selected from Online session

RN 274918-61-5 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]-3-but enyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274918-62-6 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-(2-propenylamino)propyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



17/09/2003 14:26 Print selected from Online session


IT 274918-50-2P 274918-55-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of peptide-based .alpha.-keto amides, .alpha.-keto esters, and .alpha.-diketones as HCV NS3 protease inhibitors)

RN 274918-50-2 CAPLUS

CN L-Prolinamide, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]-3-but enyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 274918-55-7 CAPLUS

CN L-Prolinamide, L-.alpha.-aspartyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-(2-propenylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



17/09/2003 14:26 Print selected from Online session

=> d bib 2

YOU HAVE REQUESTED DATA FROM FILE 'CPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 2 OF 18 CPLUS COPYRIGHT 2003 ACS on STN
AN 2000:269109 CPLUS
DN 133:43798
TI .alpha.-Keto amides, .alpha.-keto esters, and .alpha.-diketones as HCV NS3 protease inhibitors
AU Han, Wei; Hu, Zilun; Jiang, Xiangjun; Decicco, Carl P.
CS Department of Chemical and Physical Sciences, DuPont Pharmaceuticals Company, Wilmington, DE, 19880, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(8), 711-713
CODEN: BMCL8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
OS CASREACT 133:43798
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 3

YOU HAVE REQUESTED DATA FROM FILE 'CPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 3 OF 18 CPLUS COPYRIGHT 2003 ACS on STN
AN 1999:571832 CPLUS
DN 131:170645
TI Preparation of acylated enol derivatives of .alpha.-ketoesters and .alpha.-ketoamides as neutrophil-associated inflammation inhibitors
IN Peet, Norton P.; Burkhart, Joseph P.; Mehdi, Shujaath
PA Hoechst Marion Roussel, Inc., USA
SO U.S., 25 pp., Cont. of U.S. Ser. No. 754,081, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|------|----------|-----------------|--------------|
| PI | US 5948886 | A | 19990907 | US 1997-978096 | 19971125 <-- |
| | US 6172044 | B1 | 20010109 | US 1999-303965 | 19990503 |
| PRAI | US 1996-754081 | B1 | 19961120 | | |
| | US 1996-31083P | P | 19961201 | | |
| | US 1997-978096 | A1 | 19971125 | | |

OS MARPAT 131:170645
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 4

YOU HAVE REQUESTED DATA FROM FILE 'CPLUS' - CONTINUE? (Y)/N:y

17/09/2003 14:26 Print selected from Online session

L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:126925 CAPLUS
DN 130:168666
TI Preparation of peptide analogs as hepatitis C inhibitors
IN Llinas-Brunet, Montse; Bailey, Murray Douglas; Halmos, Teddy; Poupart, Marc-Andre; Tsantrizos, Youla
PA Boehringer Ingelheim (Canada) Ltd., Can.
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1


| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|----------------|--|----------|-----------------|--------------|
| PI | WO 9907734 | A2 | 19990218 | WO 1998-CA764 | 19980810 <-- |
| | WO 9907734 | A3 | 19990520 | | |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | |
| | AU 9888466 | A1 | 19990301 | AU 1998-88466 | 19980810 <-- |
| | AU 757072 | B2 | 20030130 | | |
| | EP 1012180 | A2 | 20000628 | EP 1998-939997 | 19980810 <-- |
| | R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | |
| | US 6143715 | A | 20001107 | US 1998-131433 | 19980810 <-- |
| | JP 2001512744 | T2 | 20010828 | JP 2000-506236 | 19980810 |
| | NZ 503263 | A | 20021025 | NZ 1998-503263 | 19980810 |
| | MX 200001491 | A | 20001110 | MX 2000-1491 | 20000211 <-- |
| PRAI | US 1997-55247P | P | 19970811 | | |
| | WO 1998-CA764 | W | 19980810 | | |
| OS | MARPAT | 130:168666 | | | |

=> d hitstr 3
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
IT **192193-38-7P 192193-39-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of ketoester and ketoamide acylated enol derivs. as neutrophil-assocd. inflammation inhibitors)
RN 192193-38-7 CAPLUS
CN L-Proline, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[3-amino-1-(1-methylethyl)-2,3-dioxopropyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

17/09/2003 14:26 Print selected from Online session




RN 192193-39-8 CAPLUS

CN L-Prolinamide, N-[4-[[[4-chlorophenyl]sulfonyl]amino]carbonyl]benzoyl]-L-valyl-N-[1-(1-methylethyl)-2,3-dioxo-3-(phenylamino)propyl] - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—NHPh

=> d hitstr 4

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

IT 220440-36-8P 220440-42-6P 220440-45-9P

220440-48-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide analogs as hepatitis C inhibitors)


RN 220440-36-8 CAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-aspartyl-D-.alpha.-glutamyl-L-isoleucyl-

17/09/2003 14:26 Print selected from Online session

L-valyl-N-[1-[oxo[(phenylmethyl)amino]acetyl]butyl]-4-(phenylmethoxy)-,
(4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220440-42-6 CAPLUS

CN L-Prolinamide, N-acetyl-2-cyclohexylglycyl-L-valyl-N-[1-[oxo[(phenylmethyl)amino]acetyl]butyl]-4-(phenylmethoxy)-, (4R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 220440-45-9 CAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-aspartyl-D-.alpha.-glutamyl-L-isoleucyl-L-valyl-N-[1-[oxo[(phenylmethyl)amino]acetyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


17/09/2003 14:26 Print selected from Online session



RN 220440-48-2 CAPLUS

CN L-Prolinamide, N-acetyl-2-cyclohexylglycyl-L-valyl-N-[1-[oxo[(4-pyridinylmethyl)amino]acetyl]butyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> d bib 5

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:709961 CAPLUS

DN 130:66781

TI Studies on the C-terminal of hexapeptide inhibitors of the hepatitis C virus serine protease

AU Llinas-Brunet, Montse; Bailey, Murray; Ddziel, Robert; Fazal, Gulrez; Gorys, Vida; Goulet, Sylvie; Halmos, Ted; Maurice, Roger; Poirier, Martin; Poupart, Marc-Andre; Rancourt, Jean; Thibeault, Diane; Wernic, Dominik; Lamarre, Daniel

CS Bio-Mega Research Division, Boehringer Ingelheim (Canada) Ltd., Laval, H7S 2G5, Can.

17/09/2003 14:26 Print selected from Online session

SO Bioorganic & Medicinal Chemistry Letters (1998), 8(19),
2719-2724

CODEN: BMCL8; ISSN: 0960-894X

PB Elsevier Science Ltd.

DT Journal

LA English

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib 6

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:268513 CAPLUS
DN 128:321945
TI Preparation of peptide analogs as inhibitors of serine proteases,
particularly hepatitis C virus NS3 protease
IN Tung, Roger D.; Harbeson, Scott L.; Deininger, David D.; Murcko, Mark A.;
Bhisetti, Govinda Rao; Farmer, Luc J.
PA Vertex Pharmaceuticals Inc., USA; Tung, Roger D.; Harbeson, Scott L.;
Deininger, David D.; Murcko, Mark A.; Bhisetti, Govinda Rao; Farmer, Luc
J.
SO PCT Int. Appl., 128 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|---|------|----------|-----------------|--------------|
| PI | WO 9817679 | A1 | 19980430 | WO 1997-US18968 | 19971017 <-- |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| | ZA 9709327 | A | 19980511 | ZA 1997-9327 | 19971017 <-- |
| | AU 9851477 | A1 | 19980515 | AU 1998-51477 | 19971017 <-- |
| | AU 719984 | B2 | 20000518 | | |
| | EP 932617 | A1 | 19990804 | EP 1997-946273 | 19971017 <-- |
| | EP 932617 | B1 | 20020116 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | IN 183120 | A | 19990911 | IN 1997-CA1951 | 19971017 <-- |
| | BR 9712544 | A | 19991019 | BR 1997-12544 | 19971017 <-- |
| | CN 1238780 | A | 19991215 | CN 1997-180151 | 19971017 <-- |
| | NZ 335276 | A | 20000929 | NZ 1997-335276 | 19971017 <-- |
| | JP 2001502694 | T2 | 20010227 | JP 1998-519568 | 19971017 |
| | EP 1136498 | A1 | 20010926 | EP 2001-109433 | 19971017 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | AP 1019 | A | 20011016 | AP 1999-1512 | 19971017 |
| | W: GH, KE, LS, MW, SD, SZ, UG, ZW | | | | |

17/09/2003 14:26 Print selected from Online session

| | | | |
|----------------------|-------------|----------------|--------------|
| AT 212037 | E 20020215 | AT 1997-946273 | 19971017 |
| ES 2169880 | T3 20020716 | ES 1997-946273 | 19971017 |
| EE 4023 | B1 20030415 | EE 1999-161 | 19971017 |
| NO 9901832 | A 19990617 | NO 1999-1832 | 19990416 <-- |
| US 6265380 | B1 20010724 | US 1999-293247 | 19990416 |
| KR 2000049263 | A 20000725 | KR 1999-703372 | 19990417 <-- |
| HK 1023779 | A1 20020927 | HK 2000-100690 | 20000203 |
| US 2002032175 | A1 20020314 | US 2001-875390 | 20010606 |
| US 6617309 | B2 20030909 | | |
| PRAI US 1996-28290P | P 19961018 | | |
| EP 1997-946273 | A3 19971017 | | |
| WO 1997-US18968 | W 19971017 | | |
| US 1999-293247 | A 19990416 | | |
| OS MARPAT 128:321945 | | | |


RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 6

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
IT 207001-60-3P 207001-61-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of peptide analogs as hepatitis C virus NS3 protease inhibitors)
RN 207001-60-3 CAPLUS
CN L-Prolinamide, N-(pyrazinylcarbonyl)-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-[(2-phenylethyl)amino]propyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 207001-61-4 CAPLUS
CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-valyl-L-valyl-N-[(1S)-1-ethyl-2,3-dioxo-3-[(2-phenylethyl)amino]propyl]-4-(phenylmethoxy)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

17/09/2003 14:26 Print selected from Online session



=> d bib 7

YOU HAVE REQUESTED DATA FROM FILE 'CPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 7 OF 18 CPLUS COPYRIGHT 2003 ACS on STN
AN 1997:636187 CPLUS
DN 127:293640
TI Preparation of peptidyl .alpha.-ketoamide derivatives as inhibitors of thrombosis
IN Abelman, Matthew M.; Pearson, Daniel A.; Vlasuk, George P.; Webb, Thomas R.
PA Corvas International, Inc., USA
SO U.S., 116 pp., Cont.-in-part of U.S. Ser. No. 37,574.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---------------|------------|----------|-----------------|--------------|
| PI | US 5670479 | A | 19970923 | US 1994-218329 | 19940325 <-- |
| | US 5656600 | A | 19970812 | US 1993-37574 | 19930325 <-- |
| | CA 2158989 | AA | 19940929 | CA 1994-2158989 | 19940325 <-- |
| PRAI | US 1993-37574 | | 19930325 | | |
| OS | MARPAT | 127:293640 | | | |

=> d hitstr 7

YOU HAVE REQUESTED DATA FROM FILE 'CPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 7 OF 18 CPLUS COPYRIGHT 2003 ACS on STN
IT 166247-65-0P 166247-66-1P 166247-67-2P

17/09/2003 14:26 Print selected from Online session

166247-68-3P 166247-69-4P 166247-70-7P

166247-71-8P 166247-72-9P 166247-75-2P


166247-76-3P



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptidyl ketoamide derivs. as inhibitors of thrombosis)

RN 166247-65-0 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-proyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

PAGE 1-A







PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 166247-66-1 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-A



PAGE 1-B



PAGE 1-C




17/09/2003 14:26 Print selected from Online session

RN 166247-67-2 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-68-3 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-69-4 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)₂

RN 166247-70-7 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)2

RN 166247-71-8 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)2

RN 166247-72-9 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

—CH(Pr-n)2


RN 166247-75-2 CAPLUS

CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

17/09/2003 14:26 Print selected from Online session


PAGE 1-A



PAGE 1-B



PAGE 1-C




RN 166247-76-3 CAPLUS

17/09/2003 14:26 Print selected from Online session


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

→ OMe

=> d bib 8

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
 AN 1997:491631 CAPLUS
 DN 127:95620
 TI Preparation of acylated enol derivatives of .alpha.-ketoesters and .alpha.-ketoamides as neutrophil-associated inflammation inhibitors
 IN Peet, Norton P.; Burkhart, Joseph P.; Mehdi, Shujaath
 PA Hoechst Marion Roussel, Inc., USA
 SO PCT Int. Appl., 81 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|----|------------|--|----------|-----------------|--------------|
| PI | WO 9720856 | A1 | 19970612 | WO 1996-US17752 | 19961104 <-- |
| | W: | AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | |
| | RW: | KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | |
| CA | 2239159 | AA | 19970612 | CA 1996-2239159 | 19961104 <-- |
| CA | 2239159 | C | 20020910 | | |

17/09/2003 14:26 Print selected from Online session


| | | | |
|--|-------------|------------------|--------------|
| AU 9676697 | A1 19970627 | AU 1996-76697 | 19961104 <-- |
| AU 705819 | B2 19990603 | | |
| EP 863915 | A1 19980916 | EP 1996-939555 | 19961104 <-- |
| EP 863915 | B1 20000202 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | |
| CN 1203602 | A 19981230 | CN 1996-198733 | 19961104 <-- |
| AT 189457 | E 20000215 | AT 1996-939555 | 19961104 <-- |
| JP 2000502073 | T2 20000222 | JP 1997-521265 | 19961104 <-- |
| ES 2144788 | T3 20000616 | ES 1996-939555 | 19961104 <-- |
| ZA 9609889 | A 19970617 | ZA 1996-9889 | 19961125 <-- |
| TW 419482 | B 20010121 | TW 1996-85114600 | 19961126 |
| NO 9802467 | A 19980803 | NO 1998-2467 | 19980529 <-- |
| PRAI US 1995-566196 | A 19951201 | | |
| WO 1996-US17752 | W 19961104 | | |
| OS MARPAT 127:95620 | | | |

=> d hitstr 8

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
IT 192193-38-7P 192193-39-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of ketoester and ketoamide acylated enol derivs. as
neutrophil-assocd. inflammation inhibitors)
RN 192193-38-7 CAPLUS
CN L-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-
valyl-N-[3-amino-1-(1-methylethyl)-2,3-dioxopropyl]- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 192193-39-8 CAPLUS
CN L-Prolinamide, N-[4-[[[(4-chlorophenyl)sulfonyl]amino]carbonyl]benzoyl]-L-
valyl-N-[1-(1-methylethyl)-2,3-dioxo-3-(phenylamino)propyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— NHPh

=> d bib 9

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1997:102091 CAPLUS
DN 126:199831
TI N-sulfonylarginine keto-amide compounds with antithrombotic activity
IN Webb, Thomas R.; Miller, Todd A.; Vlasuk, George P.; Abelman, Matthew M.
PA Corvas International, Inc., USA
SO U.S., 76 pp., Cont.-in-part of U.S. 5,371,072.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|-------------------|------|----------|-----------------|--------------|
| PI | US 5597804 | A | 19970128 | US 1993-139300 | 19931018 <-- |
| | US 5371072 | A | 19941206 | US 1992-962301 | 19921016 <-- |
| | AT 178044 | E | 19990415 | AT 1993-924369 | 19931018 <-- |
| | US 5869454 | A | 19990209 | US 1995-462899 | 19950605 <-- |
| PRAI | US 1992-962301 | | 19921016 | | |
| | US 1993-139300 | | 19931018 | | |
| OS | MARPAT 126:199831 | | | | |

=> d hitstr

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:n

=> d hitstr 9

17/09/2003 14:26 Print selected from Online session

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN

IT 159945-69-4P 159945-71-8P 159945-75-2P

159945-78-5P 159945-82-1P 159946-33-5P

187740-90-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate in prepn. of antithrombotic sulfonylarginine-contg. keto amide peptides)


RN 159945-69-4 CAPLUS

CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.



RN 159945-78-5 CAPLUS

CN L-Proline, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(3-phenylpropyl)amino]acetyl]butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-82-1 CAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-prolyl-(3S)-3-amino-6-[[imino(nitroamino)methyl]amino]-2-oxohexanoyl-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159946-33-5 CAPLUS

CN L-Prolinamide, N-(1-oxo-2-propylpentyl)-3-[1-[(phenylmethoxy)methyl]-1H-tetrazol-5-yl]-L-alanyl-N-[4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187740-90-5 CAPLUS

CN L-Prolinamide, N-[(2E)-3-(3-methylphenyl)-1-oxo-2-propenyl]-L-.alpha.-aspartyl-N-[(1S)-4-[[imino(nitroamino)methyl]amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




IT 159945-27-4P 159945-28-5P 159945-29-6P
159945-31-0P 159946-18-6P 159946-39-1P
187741-29-3P 187741-30-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of antithrombotic sulfonylarginine-contg. keto amide peptides)

RN 159945-27-4 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-28-5 CAPLUS

CN L-Prolinamide, N-(4-methyl-1-oxopentyl)-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-29-6 CAPLUS

CN L-Prolinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159945-31-0 CAPLUS

CN L-Prolinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-N-[4-[(aminoiminomethyl)amino]-1-[oxo[(3-phenylpropyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 159946-18-6 CAPLUS

CN L-Prolinamide, 3-(1-methyl-1H-tetrazol-5-yl)-N-(1-oxo-2-propylpentyl)-L-

17/09/2003 14:26 Print selected from Online session

alanyl-N-[4-[(imino(nitroamino)methyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 159946-39-1 CAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-L-.alpha.-aspartyl-L-prolyl-(3S)-3-amino-6-[(aminoiminomethyl)amino]-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187741-29-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-1-[4-(methylsulfonyl)-1-oxo-2-[(1-oxo-2-propylpentyl)amino]butyl]-, [2S-[1(R*),2R*(R*)]]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187741-30-6 CAPLUS

CN L-Prolinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 187740-91-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of antithrombotic sulfonylarginine-contg. keto amide peptides)

RN 187740-91-6 CAPLUS

CN L-Prolinamide, N-[(2E)-3-(3-methylphenyl)-1-oxo-2-propenyl]-L-.alpha.-aspartyl-N-[(1S)-4-[(aminoiminomethyl)amino]-1-[oxo[(2-phenylethyl)amino]acetyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



17/09/2003 14:26 Print selected from Online session

=> d bib 10

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:592180 CAPLUS
DN 125:301554
TI Poststatin, a new inhibitor of prolyl endopeptidase. V. Endopeptidase inhibitory activity of poststatin analogs
AU Tsuda, Makoto; Muraoka, Yasuhiko; Nagai, Machiko; Aoyagi, Takaaki; Takeuchi, Tomio
CS Inst. Microbial Chem., Tokyo, 141, Japan
SO Journal of Antibiotics (1996), 49(9), 890-899
CODEN: JANTAJ; ISSN: 0021-8820
PB Japan Antibiotics Research Association
DT Journal
LA English

=> d bib 11

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:157989 CAPLUS
DN 124:282995
TI Synthesis, structure, and structure-activity relationships of divalent thrombin inhibitors containing an .alpha.-keto-amide transition-state mimetic
AU Krishnan, Raman; Tulinsky, A.; Vlasuk, George P.; Pearson, Daniel; Vallar, Pureza; Bergum, Peter; Brunck, Terence K.; Ripka, William C.
CS Dep. Chemistry, Michigan State Univ., East Lansing, MI, 48824-1322, USA
SO Protein Science (1996), 5(3), 422-33
CODEN: PRCIEI; ISSN: 0961-8368
PB Cambridge University Press
DT Journal
LA English

=> d bib 12

YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1996:108206 CAPLUS
DN 124:250214
TI Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis
AU Biemond, Bart J.; Friederich, Philip W.; Levi, Marcel; Vlasuk, George P.; Buller, Harry R.; ten Cate, Jan W.
CS Center Hemostasis Thrombosis Atherosclerosis and Inflammation Research, Academic Medical Center, Amsterdam, 1105 AZ, Neth.
SO Circulation (1996), 93(1), 153-60

17/09/2003 14:26 Print selected from Online session

CODEN: CIRCAZ; ISSN: 0009-7322
PB American Heart Association
DT Journal
LA English

=> d bib 13
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1995:733186 CAPLUS
DN 123:144645
TI Preparation of peptide .alpha.-ketoamide derivatives as antithrombotics and for imaging thrombi.
IN Abelman, Matthew Mark; Pearson, Daniel Andrew; Vlasuk, George Phillip; Webb, Thomas Roy
PA Corvas International, Inc., USA
SO PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------|---|------|----------|-----------------|--------------|
| | ----- | --- | ----- | ----- | ----- |
| PI | WO 9421673 | A1 | 19940929 | WO 1994-US3312 | 19940325 <-- |
| | W: AU, CA, CN, JP, KR | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | US 5656600 | A | 19970812 | US 1993-37574 | 19930325 <-- |
| | CA 2158989 | AA | 19940929 | CA 1994-2158989 | 19940325 <-- |
| | AU 9465255 | A1 | 19941011 | AU 1994-65255 | 19940325 <-- |
| | AU 684069 | B2 | 19971204 | | |
| | EP 693083 | A1 | 19960124 | EP 1994-912880 | 19940325 <-- |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | JP 08508259 | T2 | 19960903 | JP 1994-521396 | 19940325 <-- |
| PRAI | US 1993-37574 | | 19930325 | | |
| | WO 1994-US3312 | | 19940325 | | |
| OS | MARPAT 123:144645 | | | | |


=> d hitstr 13
YOU HAVE REQUESTED DATA FROM FILE 'CAPLUS' - CONTINUE? (Y)/N:y

L12 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2003 ACS on STN
IT 166247-65-0P 166247-66-1P 166247-67-2P
166247-68-3P 166247-69-4P 166247-70-7P
166247-71-8P 166247-72-9P 166247-75-2P
166247-76-3P 166247-77-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide .alpha.-ketoamide derivs. as antithrombotics and for imaging thrombi)
RN 166247-65-0 CAPLUS
CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-


17/09/2003 14:26 Print selected from Online session

(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B




PAGE 1-B




PAGE 1-C




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 166247-66-1 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-A



PAGE 1-B



PAGE 1-C




17/09/2003 14:26 Print selected from Online session

RN 166247-67-2 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 166247-68-3 CAPLUS

CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N₆-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



PAGE 1-B



PAGE 1-C




RN 166247-69-4 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)2

RN 166247-70-7 CAPLUS


CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—CH(Pr-n)2

RN 166247-71-8 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-proyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-proyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1 - C




PAGE 1-D

$$-\text{CH}(\text{Pr}-n)_2$$


RN 166247-72-9 CAPLUS
CN L-Leucinamide, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D

—CH(Pr-n)2


RN 166247-75-2 CAPLUS

CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

17/09/2003 14:26 Print selected from Online session


PAGE 1-A



PAGE 1-B



PAGE 1 - C




RN 166247-76-3 CAPLUS

17/09/2003 14:26 Print selected from Online session


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycylglycyl-L-asparaginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D


—OMe

RN 166247-77-4 CAPLUS


CN L-Leucine, N-(1-oxo-2-propylpentyl)-L-.alpha.-aspartyl-L-.alpha.-aspartyl-L-prolyl-N6-(aminoiminomethyl)-2-oxo-(S)-3,6-diaminohexanoylglycylglycylglycylglycyl-L-arginylglycyl-L-.alpha.-aspartyl-L-phenylalanyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-tyrosyl-, 1-methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

